{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:48:03Z","timestamp":1761864483909,"version":"build-2065373602"},"reference-count":98,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), better known as COVID-19, is a highly contagious virus, transferable via air droplets from close human-human contact. The pandemic has led to over 6.5 million deaths worldwide, making it the largest global health crisis since the influenza pandemic in 1918. SARS-CoV-2 rapidly spread around the world, forcing the World Health Organization (WHO) to deem it a global health pandemic after three months of its initiation. The virus has wreaked havoc on many countries worldwide, overwhelming healthcare systems, hence damaging many economies. Even though research has progressed the understanding of the SARS-CoV-2 virus, the information gathered about the vaccine trials and their findings have been scarcely distributed to the public in a single study. The information available to scientists has therefore given researchers a pathway to building an efficacious vehicle to substantially decrease the spread of the virus. The vaccines formulated had many challenges due to multiple factors such as viral mutations and clinical trial delays. This paper will aim to educate readers on the processes that the vaccine candidates took, and better understand the procedures; additionally, we\u2019ll look at all candidates\u2019 findings that went into clinical trials, assessing, analyzing, and evaluating the 27 vaccine candidates that went into phase III trials and the 13 candidates that went into either phase I\/II trials.<\/jats:p>","DOI":"10.3390\/vaccines10122086","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:49:35Z","timestamp":1670381375000},"page":"2086","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SARS-CoV-2: An Analysis of the Vaccine Candidates Tested in Combatting and Eliminating the COVID-19 Virus"],"prefix":"10.3390","volume":"10","author":[{"given":"Laila","family":"Elmancy","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Alkhatib","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8495-3076","authenticated-orcid":false,"given":"Anis","family":"Daou","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"ref_1","unstructured":"(2022, November 15). McGill University Interdisciplinary Initiative in Infection and Immunity (MI4). 2022. How Many Types of COVID-19 Vaccines Are There? COVID-19 Vaccine Tracker. Last Updated: 2022. Available online: https:\/\/covid19.trackvaccines.org\/vaccine-types\/."},{"key":"ref_2","unstructured":"World Health Organization (2022, August 21). Coronavirus. Available online: https:\/\/www.who.int\/health-topics\/coronavirus#tab=tab_3."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s11606-020-05762-w","article-title":"Review of the clinical characteristics of coronavirus disease 2019 (COVID-19)","volume":"35","author":"Jiang","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.14740\/jocmr4518","article-title":"Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?","volume":"13","author":"Vasireddy","year":"2021","journal-title":"J. Clin. Med. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100037","DOI":"10.1016\/j.sintl.2020.100037","article-title":"Study and overview of the novel corona virus disease (COVID-19)","volume":"1","author":"Agarwal","year":"2020","journal-title":"Sens. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-020-00243-2","article-title":"COVID-19: Immunopathogenesis and Immunotherapeutics","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108427","DOI":"10.1016\/j.clim.2020.108427","article-title":"COVID-19 pathophysiology: A review","volume":"215","author":"Yuki","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/10408363.2020.1783198","article-title":"The COVID-19 pandemic","volume":"57","author":"Ciotti","year":"2020","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cca.2020.05.044","article-title":"COVID-19: Transmission, prevention, and potential therapeutic opportunities","volume":"508","author":"Lotfi","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40249-020-00646-x","article-title":"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review","volume":"9","author":"Adhikari","year":"2020","journal-title":"Infect. Dis. Poverty"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17513","DOI":"10.1073\/pnas.2008373117","article-title":"The implications of silent transmission for the control of COVID-19 outbreaks","volume":"117","author":"Moghadas","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Darby, A.C., and Hiscox, J.A. (2021). COVID-19: Variants and vaccination. BMJ, 372.","DOI":"10.1136\/bmj.n771"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2313","DOI":"10.1002\/rmv.2313","article-title":"COVID-19 vaccines and variants of concern: A review","volume":"32","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.vacune.2020.09.005","article-title":"Novel coronavirus 2019 (COVID-19) pandemic outbreak: A comprehensive review of the current literature","volume":"22","author":"Ullah","year":"2021","journal-title":"Vacunas (Engl. Ed.)"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/jmv.27634","article-title":"An exploratory study on the propagation of SARS-CoV-2 variants: Omicron is the most predominant variant","volume":"94","author":"Rathinasamy","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1377\/hlthaff.2020.02054","article-title":"Clinical Outcomes Of A COVID-19 Vaccine: Implementation over Efficacy: Study examines how definitions and thresholds of vaccine efficacy, coupled with different levels of implementation effectiveness and background epidemic severity, translate into outcomes","volume":"40","author":"Paltiel","year":"2021","journal-title":"Health Aff."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/d41586-021-00409-0","article-title":"Why COVID vaccines are so difficult to compare","volume":"591","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"ref_19","unstructured":"(2022, August 21). Coronavirus. History of Vaccines RSS. Available online: https:\/\/historyofvaccines.org\/diseases\/coronavirus."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-020-01744-7","article-title":"The COVID-19 vaccine race: Challenges and opportunities in vaccine formulation","volume":"21","author":"Wang","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"ref_21","unstructured":"Centers for Disease Control and Prevention (2022, August 21). Understanding Viral Vector COVID-19 Vaccines, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/viralvector.html."},{"key":"ref_22","unstructured":"IntechOpen (2022, August 21). Plasmid-Based DNA Vaccines. Available online: https:\/\/www.intechopen.com\/chapters\/61091."},{"key":"ref_23","unstructured":"IntechOpen (2022, August 21). Trained Immunity-Based Vaccines: A Ready-To-Act Strategy to Tackle Viral Outbreaks. Available online: https:\/\/www.intechopen.com\/chapters\/74915."},{"key":"ref_24","unstructured":"Centers for Disease Control and Prevention (2022, August 21). Understanding mrna COVID-19 Vaccines, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/mrna.html."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.7150\/ijbs.59233","article-title":"mRNA vaccines for COVID-19: What, why and how","volume":"17","author":"Park","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_26","unstructured":"(2022, September 11). Biosystems ACRO. An Overview of Different COVID-19 Vaccines. ACRO. Last Updated: 9 December 2021. Available online: https:\/\/www.acrobiosystems.com\/A1374-An-Overview-of-Different-COVID-19-Vaccines.html?gclid=Cj0KCQjwj."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"585354","DOI":"10.3389\/fimmu.2020.585354","article-title":"A Review of the Progress and Challenges of Developing a Vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s12098-020-03475-w","article-title":"Vaccine against COVID-19 disease\u2013present status of development","volume":"87","author":"Dutta","year":"2020","journal-title":"Indian J. Pediatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials","volume":"27","author":"Kim","year":"2021","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.chom.2020.09.017","article-title":"Accelerated preclinical paths to support rapid development of COVID-19 therapeutics","volume":"28","author":"Grobler","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_31","unstructured":"(2022, August 21). Learn more about vaccine clinical trials. COVID. Available online: https:\/\/covid19.trackvaccines.org\/trials-vaccine-testing\/#:~:text=Vaccines%20are%20tested%20in%20phase,outweigh%20any%20potential%20side%20effects."},{"key":"ref_32","unstructured":"(2022, August 21). Mary Van Beusekom | News Writer | CIDRAP News | Jul 15 2020. Hopeful results from phase 1 moderna COVID vaccine trial. CIDRAP. Available online: https:\/\/www.cidrap.umn.edu\/news-perspective\/2020\/07\/hopeful-results-phase-1-moderna-covid-vaccine-trial."},{"key":"ref_33","unstructured":"(2022, August 21). News 1 June, Suvoda. Moderna Starts Dosing in Phase II COVID-19 vaccine trial. Clinical Trials Arena. Available online: https:\/\/www.clinicaltrialsarena.com\/news\/moderna-phaseii-vaccine-trial\/."},{"key":"ref_34","first-page":"100241","article-title":"An open, non-randomised, phase 1\/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine \u201cSputnik Light\u201d for prevention of coronavirus infection in healthy adults","volume":"11","author":"Tukhvatulin","year":"2021","journal-title":"Lancet Reg. Health-Eur."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26. COV2. S COVID-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_36","unstructured":"(2022, August 21). Johnson & Johnson. Content Lab U.S. Available online: https:\/\/www.jnj.com\/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u-s."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_38","unstructured":"(2022, August 21). Evidence Assessment: Sinopharm\/BBIBP COVID-19 Vaccine. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/sage\/2021\/april\/2_sage29apr2021_critical-evidence_sinopharm.pdf?sfvrsn=3dfe32c1_5."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1186\/s13063-020-04775-4","article-title":"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac\u2013PROFISCOV: A structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Palacios","year":"2020","journal-title":"Trials"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cengiz, B., Say\u0131l\u0131r M, \u00dc., Zengin, N.Y., K\u00fc\u00e7\u00fck, \u00d6.N., and Soylu, A.R. (2022). Does the COVID-19 Vaccination Rate Change According to the Education and Income: A Study on Vaccination Rates in Cities of Turkey between 2021-September and 2022-February. Vaccines, 10.","DOI":"10.3390\/vaccines10111933"},{"key":"ref_42","unstructured":"The Melbourne Vaccine Education Centre (MVEC) (2022, August 21). Nuvaxovid (novavax) COVID-19 Vaccine. Available online: https:\/\/mvec.mcri.edu.au\/references\/novavax-covid-19-vaccine\/."},{"key":"ref_43","unstructured":"(2022, August 21). Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom. Novavax Investor Relations. Available online: https:\/\/ir.novavax.com\/2020-09-24-Novavax-Initiates-Phase-3-Efficacy-Trial-of-COVID-19-Vaccine-in-the-United-Kingdom."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-COV-2 vaccines strategies: A Comprehensive Review of Phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"Npj Vaccines"},{"key":"ref_45","unstructured":"(2022, August 21). Whole-virion inactivated SARS-COV-2 vaccine (BBV152) for COVID-19 in Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04471519."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_48","unstructured":"(2022, August 21). History of changes for study: NCT04641481, Available online: https:\/\/clinicaltrials.gov\/ct2\/history\/NCT04641481?V_1=View."},{"key":"ref_49","unstructured":"(2022, August 21). Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04741061?id=NCT04733807%2BOR%2BNCT04718467%2BOR%2BNCT04706156%2BOR%2BNCT04743947%2BOR%2BNCT04715997%2BOR%2BNCT04732468%2BOR%2BNCT04713488%2BOR%2BNCT04741061&draw=2&rank=2&load=cart."},{"key":"ref_50","unstructured":"(2022, August 21). Strategies for Combining the First Component of Sputnik V with Other Adenoviral or Mrna-Based Vaccines, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05027672."},{"key":"ref_51","unstructured":"(2022, August 21). Single Dose Vaccine, Sputnik Light, Authorized for Use in Russia. Sputnik V\u2014The First Registered Vaccine against COVID-19. Official Website Vaccine against Coronavirus Sputnik, V. Available online: https:\/\/sputnikvaccine.com\/newsroom\/pressreleases\/single-dose-vaccine-sputnik-light-authorized-for-use-in-russia\/."},{"key":"ref_52","unstructured":"(2022, August 21). Phase I\/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04840992."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_54","unstructured":"(2022, August 21). Phase III Trial of a COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04526990."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.53854\/liim-2903-3","article-title":"Review of COVID-19 viral vector-based vaccines and COVID-19 variants","volume":"29","author":"Vanaparthy","year":"2021","journal-title":"Le Infez. Med."},{"key":"ref_56","unstructured":"(2022, August 22). Chinese clinical trial register (chictr)\u2014The World Health Organization International Clinical Trials Registered Organization Registered Platform. Available online: http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=52227."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Adverse reactions and antibody responses to an inactivated SARS-COV-2 vaccine-interim trial analyses","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"ref_58","unstructured":"(2022, August 22). A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04510207."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial","volume":"326","author":"Zhang","year":"2021","journal-title":"JAMA"},{"key":"ref_60","unstructured":"Registro P\u00fablico Cubano de Ensayos Cl\u00ednicos (2022, August 22). Abdala Clinical Study. Available online: https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000346-En."},{"key":"ref_61","unstructured":"(2022, August 22). Abdala Clinical Study\u2014Phase III: Registro P\u00fablico Cubano de Ensayos Cl\u00ednicos. Available online: https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000359-En."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Bernal, F., Ricardo-Cobas, M.C., Mart\u00edn-Bauta, Y., Navarro-Rodr\u00edguez, Z., Pi\u00f1era-Mart\u00ednez, M., Quintana-Guerra, J., Urrutia-P\u00e9rez, K., Urrutia-P\u00e9rez, K., Ch\u00e1vez-Chong, C.O., and Azor-Hern\u00e1ndez, J.L. (2022, August 22). Safety, tolerability, and immunogenicity of a SARS-COV-2 recombinant spike protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (Abdala Study). medRxiv. Cold Spring Harbor Laboratory Press. Available online: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.11.30.21267047v2.","DOI":"10.1016\/j.eclinm.2022.101383"},{"key":"ref_63","unstructured":"(2022, August 22). PMC E. Europe PMC. Available online: https:\/\/europepmc.org\/article\/med\/34516531."},{"key":"ref_64","unstructured":"(2022, August 22). Study of the Safety, Reactogenicity and Immunogenicity of \u201cEpiVacCorona\u201d Vaccine for the Prevention of COVID-19, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04527575."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15789\/2220-7619-ASB-1699","article-title":"A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the \u201cepivaccorona\u201d vaccine for the prevention of COVID-19, in volunteers aged 18\u201360 years (phase I\u2013II)","volume":"11","author":"Ryzhikov","year":"2021","journal-title":"Russ. J. Infect. Immun."},{"key":"ref_66","unstructured":"(2022, August 22). Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04780035?term=vaccine&cond=Covid19&draw=2."},{"key":"ref_67","unstructured":"(2022, August 22). Decision Analysis of the COVID-19 Vaccines\u2014Sciendo. Available online: https:\/\/sciendo.com\/pdf\/10.2478\/ebtj-2021-0017."},{"key":"ref_68","unstructured":"(2022, August 22). Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04445194."},{"key":"ref_69","unstructured":"(2022, August 22). Clinical Study of Recombinant Novel Coronavirus Vaccine, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04466085."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Yang, S., Li, Y., Dai, L., Wang, J., He, P., Li, C., Fang, X., Wang, C., Zhao, X., and Huang, E. (2022, August 22). Safety and Immunogenicity of a Recombinant Tandem-Repeat Dimeric RBD-Based Protein Subunit Vaccine (ZF2001) against COVID-19 in Adults: Two Randomised, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7990482\/.","DOI":"10.1016\/S1473-3099(21)00127-4"},{"key":"ref_71","unstructured":"(2022, August 22). A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04646590."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"771242","DOI":"10.3389\/fimmu.2021.771242","article-title":"Immune evasive effects of SARS-COV-2 variants to COVID-19 emergency used vaccines","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_73","unstructured":"Registro P\u00fablico Cubano de Ensayos Cl\u00ednicos (2022, August 22). Soberana 02. Available online: https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000340-En."},{"key":"ref_74","unstructured":"Registro P\u00fablico Cubano de Ensayos Cl\u00ednicos (2022, August 22). Soberana 02A. Available online: https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000347-En."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2022.05.082","article-title":"Safety and immunogenicity of anti-SARS cov-2 vaccine Soberana 02 in homologous or heterologous scheme","volume":"40","year":"2022","journal-title":"Vaccine"},{"key":"ref_76","unstructured":"Registro P\u00fablico Cubano de Ensayos Cl\u00ednicos (2022, August 22). Soberana 02-FASEIII. Available online: https:\/\/rpcec.sld.cu\/trials\/RPCEC00000354-En."},{"key":"ref_77","unstructured":"Toledo-Romani, M.E., Garcia-Carmenate, M., Silva, C.V., Baldoquin-Rodriguez, W., P\u00e9rez, M.M., Gonzalez, M.C.R., Moreno, B.P., Mendoza Hern\u00e1ndez, I.C., Gonz\u00e1lez-Mujica Romero, R., and Sam\u00f3n Tabio, O. (2022, August 22). Efficacy and safety of Soberana 02, a COVID-19 conjugate vaccine in heterologous three doses combination. medRxiv. Cold Spring Harbor Laboratory Press. Available online: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.10.31.21265703v1."},{"key":"ref_78","unstructured":"(2022, August 22). Oxford\/AstraZeneca: Vaxzevria. COVID. Available online: https:\/\/covid19.trackvaccines.org\/vaccines\/4\/."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162B2 mrna COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_80","unstructured":"(2022, August 22). Define_Me. Available online: https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(21)00358-8\/fulltext."},{"key":"ref_81","unstructured":"(2021, January 04). About the Oxford COVID-19 Vaccine. Available online: https:\/\/www.research.ox.ac.uk\/Article\/2020-07-19-the-oxford-covid-19-vaccine."},{"key":"ref_82","unstructured":"(2021, January 04). Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate against COVID-19 and Commence Pivotal Phase 2\/3 Global Study. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0."},{"key":"ref_83","unstructured":"Correspondent, S. (2022, August 22). Zycov-D, India\u2019s First COVID-19 Vaccine for Those Above 12, gets Nod. The Hindu. Available online: https:\/\/www.thehindu.com\/news\/national\/zycov-d-indias-first-covid-19-vaccine-for-those-above-12-gets-nod\/article61427762.ece."},{"key":"ref_84","unstructured":"(2022, August 22). Organization of Defensive Innovation and Research: Fakhravac (MIVAC). Available online: https:\/\/covid19.trackvaccines.org\/vaccines\/97\/."},{"key":"ref_85","unstructured":"(2022, August 22). Health Institutes of Turkey: Turkovac. Available online: https:\/\/covid19.trackvaccines.org\/vaccines\/77\/."},{"key":"ref_86","unstructured":"World Health Organization (2022, August 22). The Sinopharm COVID-19 Vaccine: What You Need to Know. Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-sinopharm-covid-19-vaccine-what-you-need-to-know."},{"key":"ref_87","unstructured":"(2022, August 22). Corbevax COVID-19 Vaccine. Welcome to Precision Vaccinations. Available online: https:\/\/www.precisionvaccinations.com\/vaccines\/corbevax-covid-19-vaccine#:~:text=In%20the%20pivotal%20Phase%20III,the%20globally%20dominant%20Delta%20variant."},{"key":"ref_88","unstructured":"Zimmer, C., Corum, J., and Wee S-lee Kristoffersen, M. (2022, August 22). Coronavirus Vaccine Tracker.  The New York Times, 31 August 2020. Available online: https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2666-5247(21)00358-X","article-title":"Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: An interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults","volume":"3","author":"Ahn","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_90","unstructured":"(2022, August 24). Tuebingen: Covac-1. Available online: https:\/\/covid19.trackvaccines.org\/vaccines\/41\/."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00324-5","article-title":"Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models","volume":"6","author":"Kalnin","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"108162","DOI":"10.1016\/j.intimp.2021.108162","article-title":"A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines","volume":"100","author":"Ghasemiyeh","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.13005\/bpj\/2214","article-title":"The recent updates on approaches and clinical trials status of COVID-19 vaccines developed globally","volume":"14","author":"Chaudhary","year":"2021","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Lorincz","year":"2021","journal-title":"Npj Vaccines"},{"key":"ref_95","unstructured":"Bayer, M. (2022, August 24). ICOSAVAX\u2019s COVID-19 Shot Fails to Deliver in Early Data, Spurring Debate About \u2018fatal flaw\u2019 in Platform. Fierce Biotech. Available online: https:\/\/www.fiercebiotech.com\/biotech\/icosavax-covid-jab-underwhelms-early-company-holds-out-hope."},{"key":"ref_96","unstructured":"(2022, August 24). Covepit COVID-19 Vaccine. Welcome to Precision Vaccinations. Available online: https:\/\/www.precisionvaccinations.com\/vaccines\/covepit-covid-19-vaccine."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Patel, V., and Patel, K. (2021). Study of Awareness Regarding COVID-19 Vaccines among General Population, Preprint.","DOI":"10.21203\/rs.3.rs-537278\/v1"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Ghasemi, S., Naderi Saffar, K., Ebrahimi, F., Khatami, P., Monazah, A., Alizadeh, G.A., Ettehadi, H.A., Rad, I., Nojehdehi, S., and Kehtari, M. (2021). Development of inactivated FAKHRAVAC\u00ae vaccine against SARS-CoV-2 virus: Preclinical study in animal models. Vaccines, 9.","DOI":"10.3390\/vaccines9111271"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2086\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:35:28Z","timestamp":1760146528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":98,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["vaccines10122086"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10122086","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2022,12,7]]}}}